The CMTA’s STAR Advisory Board comprises a Scientific Advisory Board, a Therapy Expert Board and a Clinical Expert Board.

The Scientific Advisory Board (SAB) provides scientific input for ongoing or proposed projects and evaluates:

The scientific status of current CMTA-funded research, identifying the scientific basis of target strategies for each CMT subtype.
Research proposals for their scientific background and the soundness of the research strategy.
The progress of research teams, recommending changes in research strategies as needed.

The Therapy Expert Board (TEB) evaluates the translational quality of ongoing and proposed projects and examines:

The pharmacological approach of disease area project team efforts.
The potential to form strategic alliances with pharmaceutical partners.
The preclinical strategy, particularly its contribution to clinical testing approaches.
The TEB may also take an active role in managing and monitoring strategic alliances.

The Clinical Expert Board (CEB) provides expert guidance and support to the CMTA’s alliance partners, helping to assure the success of clinical trials by:

Providing the natural history and clinical expertise to design, develop and enable clinical trials.
Collaborating with scientists in the development of clinical biomarkers.
Ensuring the adequate recruitment of carefully evaluated patients and experienced investigators to conduct these trials.

Membership

	SAB	TEB	CEB
John Svaren, PhD, SAB Chair University of Wisconsin
Frank Baas, MD, PhD University of Amsterdam, The Netherlands
Robert H. Baloh, MD, PhD Cedars-Sinai Medical Center
Maurizio D’Antonio, PhD San Raffaele Scientific Institute, DIBIT, Milan, Italy
Beverly Davidson, PhD University of Pennsylvania
M. Laura Feltri, MD University at Buffalo
Steven Gray, PhD University of Texas Southwestern Medical Center
Scott Harper, PhD The Ohio State University School of Medicine
Kleopas Kleopa, MD Cyprus Institute of Neurology & Genetics
Jun Li, MD, PhD Vanderbilt University
Rudolph Martini, PhD University of Würzburg, Germany
Albee Messing, VMD, PhD University of Wisconsin
Klaus-Armin Nave, PhD Max Planck Institute for Experimental Medicine University of Göttingen, Germany
Brian Popko, MD University of Chicago
Mario Saporta, MD, PhD University of Miami
Steven S. Scherer, MD, PhD University of Pennsylvania
Lawrence Wrabetz, MD University at Buffalo
Stephan Züchner, MD, PhD University of Miami
Mark Scheideler, PhD, TEB Chair HumanFirst Therapeutics LLC
David Herrmann, MD University of Rochester
Tage Honore, PhD Aestus Therapeutics Inc.
Christopher Klein, MD Mayo Clinic, Rochester, Minnesota
Lars J. S. Knutsen, PhD Discovery Pharma Consulting LLC
Claes Wahlestedt, MD, PhD University of Miami
Michael E. Shy, MD, CEB Chair University of Iowa
Mary Reilly, MD, CEB Co-Chair National Hospital, London, England
Richard Finkel, MD Nemour’s Children’s Hospital, Orlando, Florida
Davide Pareyson, MD Besta Institute, Milan, Italy
Joshua Burns, PhD University of Sydney, Australia
Michael McDermott, PhD, Consultant University of Rochester Medical Center